The United States could take steps to cut the cost of expensive medicines in the next few years, but the chief of Mayne Pharma says the pharmaceutical producer would take these price drops in its stride.

Chief executive Scott Richards says he foresees US drug price reform in the next three years, but this would not hurt Mayne Pharma's bottom line because 70.1 per cent of its sales come from cheaper generic medicines rather than pricey branded products.